{"id":"tp-56403","type":"article-newspaper","title":"Lineage Cell Therapeutics Adds HUNT1, Projects Funding Into Q2 2028","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/56403","datePublished":"2026-11-13T06:38:44.000Z","dateModified":"2026-11-13T06:38:44.000Z","language":"en","abstract":"The company reported $45.2 million in cash, cash equivalents and marketable securities. HUNT1 is an enrolling Phase Ib/IIa program for Huntington’s disease.","section":"Business","references":[]}